Annual CFO
-$15.71 M
+$11.52 M+42.30%
December 31, 2024
Summary
- As of March 11, 2025, YMAB annual cash flow from operations is -$15.71 million, with the most recent change of +$11.52 million (+42.30%) on December 31, 2024.
- During the last 3 years, YMAB annual CFO has risen by +$86.84 million (+84.68%).
- YMAB annual CFO is now -40.73% below its all-time high of -$11.17 million, reached on December 31, 2016.
Performance
YMAB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$1.87 M
+$8.79 M+82.47%
December 31, 2024
Summary
- As of March 11, 2025, YMAB quarterly cash flow from operations is -$1.87 million, with the most recent change of +$8.79 million (+82.47%) on December 31, 2024.
- Over the past year, YMAB quarterly CFO has stayed the same.
- YMAB quarterly CFO is now -727.52% below its all-time high of $298.00 thousand, reached on June 30, 2024.
Performance
YMAB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$15.71 M
+$6.17 M+28.18%
December 31, 2024
Summary
- As of March 11, 2025, YMAB TTM cash flow from operations is -$15.71 million, with the most recent change of +$6.17 million (+28.18%) on December 31, 2024.
- Over the past year, YMAB TTM CFO has stayed the same.
- YMAB TTM CFO is now -137.80% below its all-time high of -$6.61 million, reached on March 31, 2018.
Performance
YMAB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
YMAB Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +42.3% | 0.0% | 0.0% |
| 3 y3 years | +84.7% | +78.4% | +79.3% |
| 5 y5 years | +78.6% | +78.4% | +79.3% |
YMAB Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +84.7% | -727.5% | +94.5% | -25.2% | +84.7% |
| 5 y | 5-year | at high | +84.7% | -727.5% | +94.5% | -25.2% | +84.7% |
| alltime | all time | -40.7% | +84.7% | -727.5% | +94.5% | -137.8% | +84.7% |
Y-mAbs Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$15.71 M(-42.3%) | -$1.87 M(-82.5%) | -$15.71 M(-28.2%) |
| Sep 2024 | - | -$10.66 M(-3678.9%) | -$21.88 M(+74.3%) |
| Jun 2024 | - | $298.00 K(-108.6%) | -$12.55 M(-28.6%) |
| Mar 2024 | - | -$3.48 M(-56.7%) | -$17.59 M(-35.4%) |
| Dec 2023 | -$27.23 M(-64.1%) | -$8.04 M(+500.6%) | -$27.23 M(-2.2%) |
| Sep 2023 | - | -$1.34 M(-71.7%) | -$27.86 M(-39.1%) |
| Jun 2023 | - | -$4.73 M(-63.9%) | -$45.75 M(-28.6%) |
| Mar 2023 | - | -$13.12 M(+51.5%) | -$64.12 M(-15.5%) |
| Dec 2022 | -$75.92 M(-26.0%) | -$8.66 M(-55.0%) | -$75.92 M(-24.9%) |
| Sep 2022 | - | -$19.23 M(-16.7%) | -$101.12 M(+1.2%) |
| Jun 2022 | - | -$23.10 M(-7.3%) | -$99.96 M(+4.5%) |
| Mar 2022 | - | -$24.93 M(-26.4%) | -$95.62 M(-6.8%) |
| Dec 2021 | -$102.56 M | -$33.86 M(+87.3%) | -$102.56 M(+18.7%) |
| Sep 2021 | - | -$18.08 M(-3.6%) | -$86.39 M(-6.6%) |
| Jun 2021 | - | -$18.76 M(-41.1%) | -$92.46 M(-8.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$31.86 M(+80.1%) | -$101.34 M(+11.1%) |
| Dec 2020 | -$91.23 M(+24.1%) | -$17.70 M(-26.7%) | -$91.23 M(-7.0%) |
| Sep 2020 | - | -$24.14 M(-12.6%) | -$98.11 M(+2.9%) |
| Jun 2020 | - | -$27.64 M(+27.0%) | -$95.36 M(+16.6%) |
| Mar 2020 | - | -$21.76 M(-11.5%) | -$81.77 M(+11.3%) |
| Dec 2019 | -$73.50 M(+78.3%) | -$24.58 M(+14.9%) | -$73.50 M(+17.6%) |
| Sep 2019 | - | -$21.39 M(+52.4%) | -$62.49 M(+24.3%) |
| Jun 2019 | - | -$14.04 M(+4.1%) | -$50.29 M(+4.5%) |
| Mar 2019 | - | -$13.48 M(-0.7%) | -$48.10 M(+16.7%) |
| Dec 2018 | -$41.23 M(+159.8%) | -$13.58 M(+47.8%) | -$41.23 M(+49.1%) |
| Sep 2018 | - | -$9.19 M(-22.5%) | -$27.65 M(+49.8%) |
| Jun 2018 | - | -$11.86 M(+79.4%) | -$18.46 M(+179.4%) |
| Mar 2018 | - | -$6.61 M | -$6.61 M |
| Dec 2017 | -$15.87 M(+42.1%) | - | - |
| Dec 2016 | -$11.17 M | - | - |
FAQ
- What is Y-mAbs Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual CFO year-on-year change?
- What is Y-mAbs Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly CFO year-on-year change?
- What is Y-mAbs Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics TTM CFO year-on-year change?
What is Y-mAbs Therapeutics annual cash flow from operations?
The current annual CFO of YMAB is -$15.71 M
What is the all time high annual CFO for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual cash flow from operations is -$11.17 M
What is Y-mAbs Therapeutics annual CFO year-on-year change?
Over the past year, YMAB annual cash flow from operations has changed by +$11.52 M (+42.30%)
What is Y-mAbs Therapeutics quarterly cash flow from operations?
The current quarterly CFO of YMAB is -$1.87 M
What is the all time high quarterly CFO for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly cash flow from operations is $298.00 K
What is Y-mAbs Therapeutics quarterly CFO year-on-year change?
Over the past year, YMAB quarterly cash flow from operations has changed by $0.00 (0.00%)
What is Y-mAbs Therapeutics TTM cash flow from operations?
The current TTM CFO of YMAB is -$15.71 M
What is the all time high TTM CFO for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high TTM cash flow from operations is -$6.61 M
What is Y-mAbs Therapeutics TTM CFO year-on-year change?
Over the past year, YMAB TTM cash flow from operations has changed by $0.00 (0.00%)